Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121682 | 0.86 | GAA (0.42) | GAACYP1A2KDM4EPOLBRAB9A | |
| SCHEMBL7274660 | 0.83 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL118407 | 0.82 | GAA (0.73) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL8610256 | 0.81 | GAA (0.71) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL25262974 | 0.79 | GAA (0.73) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL8609864 | 0.79 | GAA (0.68) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL12775883 | 0.79 | GAA (0.68) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL8607119 | 0.78 | GAA (0.67) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL101291 | 0.78 | GAA (1.00) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL8607711 | 0.76 | GAA (0.64) | GAACYP1A2KDM4EPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906221-B1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RES INST (US) | 2019-05-15 | — | — | EP | disclosed |
| US-9969743-B2 | Urea and amide derivatives of aminoalkylpiperazines and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170190711-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-07-06 | — | — | US | disclosed |
| US-9598387-B2 | Urea and amide derivatives of aminoalkylpiperazines and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150232435-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2906221-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | Southern Research Institute (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014059265-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2014-04-17 | — | — | WO | disclosed |
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2424866-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS -SECRETASE INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126745-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190711-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | HTR2C, HTR4, HTR2A | GAA 2092/4885CYP1A2 178/4885KDM4E 1635/4885 |
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | GAA 30/4885CYP1A2 722/4885KDM4E 2967/4885 |
| US-20150232435-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | DRD2, CHRM2, NPY2R | GAA 1501/4885CYP1A2 528/4885KDM4E 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.